{"title":"溶酶体贮积病:诱导自噬的天然产物","authors":"Chandani Chandrana, Tahib Habshi, Arun Soni, Sanjeev Acharya","doi":"10.2174/1574885519666230915103100","DOIUrl":null,"url":null,"abstract":"Background: The link between autophagy and lysosomal function has been well-recognised in recent dec-ades; defective autophagy and lysosomal function lead to various disorders, notably Lysoso-mal Storage Disorders (LSDs). The malfunction of multiple mechanistic pathways influences the contribution of LSDs. Different ways are employed in such situations, but one novel ap-proach could resolve the problem by inducing the autophagic pathway, which aids in main-taining proper autophagy and lysosomal degradation function. Method: Autophagic Inducer functions on the activation of Transcriptional factor EB (TFEB) and its mechanism; mTOR Complex Inhibition dependently or independently may repair the mal-function of the entire mechanism. Finding a potential autophagic inducer is still a work in progress, but targeting TFEB and mTOR could redefine LSD treatment. The development of experimentally available TFEB modulators could enhance autophagic flux promote lysosomal function and increase lysosomal biogenesis and can be a promising technique for treating ill-nesses caused by ALP dysfunction, such as lysosomal storage disorder. Result: MTORC1 suppression causes TFEB to be transported to the nucleus and transcription of mul-tiple genes involved in the formation of autophagosomes and lysosomes, indicating that MTORC1 has positive effects in treating lysosomal storage diseases such as Pompe disease, Batton disease, Fabry disease, etc. thus modulating autophagy attenuates the above condi-tion. Conclusion: This review comprises autophagy and lysosome association, and their malfunction leads to various lysosomal diseases. Several natural products are also discussed, which can be possible treatment options.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":"13 1","pages":"0"},"PeriodicalIF":0.3000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lysosomal storage diseases: Natural products inducing autophagy\",\"authors\":\"Chandani Chandrana, Tahib Habshi, Arun Soni, Sanjeev Acharya\",\"doi\":\"10.2174/1574885519666230915103100\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The link between autophagy and lysosomal function has been well-recognised in recent dec-ades; defective autophagy and lysosomal function lead to various disorders, notably Lysoso-mal Storage Disorders (LSDs). The malfunction of multiple mechanistic pathways influences the contribution of LSDs. Different ways are employed in such situations, but one novel ap-proach could resolve the problem by inducing the autophagic pathway, which aids in main-taining proper autophagy and lysosomal degradation function. Method: Autophagic Inducer functions on the activation of Transcriptional factor EB (TFEB) and its mechanism; mTOR Complex Inhibition dependently or independently may repair the mal-function of the entire mechanism. Finding a potential autophagic inducer is still a work in progress, but targeting TFEB and mTOR could redefine LSD treatment. The development of experimentally available TFEB modulators could enhance autophagic flux promote lysosomal function and increase lysosomal biogenesis and can be a promising technique for treating ill-nesses caused by ALP dysfunction, such as lysosomal storage disorder. Result: MTORC1 suppression causes TFEB to be transported to the nucleus and transcription of mul-tiple genes involved in the formation of autophagosomes and lysosomes, indicating that MTORC1 has positive effects in treating lysosomal storage diseases such as Pompe disease, Batton disease, Fabry disease, etc. thus modulating autophagy attenuates the above condi-tion. Conclusion: This review comprises autophagy and lysosome association, and their malfunction leads to various lysosomal diseases. Several natural products are also discussed, which can be possible treatment options.\",\"PeriodicalId\":11004,\"journal\":{\"name\":\"Current Drug Therapy\",\"volume\":\"13 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2023-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Drug Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1574885519666230915103100\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574885519666230915103100","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Background: The link between autophagy and lysosomal function has been well-recognised in recent dec-ades; defective autophagy and lysosomal function lead to various disorders, notably Lysoso-mal Storage Disorders (LSDs). The malfunction of multiple mechanistic pathways influences the contribution of LSDs. Different ways are employed in such situations, but one novel ap-proach could resolve the problem by inducing the autophagic pathway, which aids in main-taining proper autophagy and lysosomal degradation function. Method: Autophagic Inducer functions on the activation of Transcriptional factor EB (TFEB) and its mechanism; mTOR Complex Inhibition dependently or independently may repair the mal-function of the entire mechanism. Finding a potential autophagic inducer is still a work in progress, but targeting TFEB and mTOR could redefine LSD treatment. The development of experimentally available TFEB modulators could enhance autophagic flux promote lysosomal function and increase lysosomal biogenesis and can be a promising technique for treating ill-nesses caused by ALP dysfunction, such as lysosomal storage disorder. Result: MTORC1 suppression causes TFEB to be transported to the nucleus and transcription of mul-tiple genes involved in the formation of autophagosomes and lysosomes, indicating that MTORC1 has positive effects in treating lysosomal storage diseases such as Pompe disease, Batton disease, Fabry disease, etc. thus modulating autophagy attenuates the above condi-tion. Conclusion: This review comprises autophagy and lysosome association, and their malfunction leads to various lysosomal diseases. Several natural products are also discussed, which can be possible treatment options.
期刊介绍:
Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.